Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study

Basit Öğe Kaydı
dc.contributor.authorBilir, Cemil
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorUçar, Mahmut
dc.contributor.authorBerk, Veli
dc.contributor.authorYıldız, Yaşar
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorİnanç İmamoğlu, Gökşen
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorArpacı, Erkan
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorKarcı, Ebru
dc.contributor.authorTemiz, Süleyman
dc.contributor.authorNayır, Erdinç
dc.contributor.authorOktay, Esin
dc.contributor.authorDal, Pınar
dc.contributor.authorPetekkaya, İbrahim
dc.contributor.authorVarım, Ceyhun
dc.contributor.authorCinemre, Hakan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:59Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:59Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000399505100004
dc.descriptionPubMed ID: 28333566
dc.description.abstractBackground: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.
dc.identifier.citationBilir, C., Yıldız, İ., Bilici, A., Uçar, M., Berk, V., Yıldız, Y. ... Cinemre, H. (2017). Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study. Cancer Investigation, 35(4), 248-255. https://dx.doi.org/10.1080/07357907.2017.1292518
dc.identifier.doi10.1080/07357907.2017.1292518
dc.identifier.endpage255
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.issue4
dc.identifier.scopusqualityQ2
dc.identifier.startpage248
dc.identifier.urihttps://dx.doi.org/10.1080/07357907.2017.1292518
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2119
dc.identifier.volume35
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Inc.
dc.relation.ispartofCancer Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectHemoglobin
dc.subjectPredictive
dc.subjectRenal Cell Carcinoma
dc.subjectSurvival
dc.subjectTyrosine Kinase Inhibitor
dc.titleIs change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilicii-Ahmet-2017.pdf
Boyut:
442.06 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu